Treatment-Resistant Depression Treatment Market Size, Share & Growth Analysis, [2030] | With CAGR of 11.0%
December 11, 2023 08:48 ET
|
Fortune Business Insights
Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a...
Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus, Novartis, Relmada, Beckley Psytech, COMPASS, Axsome, Celon Pharma
October 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...
With 9.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 2.83 Billion by 2029
November 04, 2022 06:39 ET
|
Fortune Business Insights
Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
May 23, 2022 07:00 ET
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
May 03, 2022 07:00 ET
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 19, 2022 07:00 ET
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
January 04, 2022 07:00 ET
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
COMPASS Pathways announces changes in Executive Team
December 16, 2021 07:40 ET
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 13, 2021 07:00 ET
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 03, 2021 07:00 ET
|
COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...